NDAORALTABLETPriority Review
Approved
Jun 1964
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Data completeness
4/8 — Partial
Priority Review
AMICAR (aminocaproic acid) by Hikma. Approved for antifibrinolytic agent [epc]. First approved in 1964.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMICAR (aminocaproic acid) is an oral antifibrinolytic agent approved in 1964 that works by inhibiting fibrinolysis to reduce bleeding. It is indicated for patients at risk of or experiencing excessive bleeding, particularly in surgical and trauma settings. The drug prevents the breakdown of blood clots by blocking plasminogen activation.
$0.060MPart D
LOE ApproachingMinimal commercial activity with only $60K in Part D spending suggests a mature, low-volume product with limited team expansion.
Mechanism of Action
Pharmacologic Class:
Antifibrinolytic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching loss of exclusivity, AMICAR offers minimal career growth or expansion opportunities. Roles on this product are primarily focused on defending market share, managing generic transition, and operational efficiency rather than innovation or team growth.
Product ManagerField Sales Representative
Worked on AMICAR at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.